Skip to main content

CAR T cell Therapy Market with Latest Development, Opportunity and Trend Analysis by Top Key Players

Global CAR T cell Therapy Market is projected to reach USD 8716.06 Million by 2025 at a CAGR of 58.52% during the review period from 2019 to 2025. Chimeric Antigen Receptor (CAR) T Cell Therapy is an immunotherapy used for cancer treatment. In this therapy, T cells from patient body are isolated and inserted in the CAR gene so that the gene for the specific receptor binds to a certain protein on the patient’s cancer cells.
Growing prevalence of cancer across the world, technological advancement for advanced & reliable treatment for cancer, and rise in the number of cell therapy clinical studies are driving the growth of the global CAR T Cell Therapy market. According to the National Cancer Institute, it is estimated that 1,735,350 new cases of cancer were diagnosed, and 609,640 deaths were reported in the US in 2018. Moreover, the growing pharmaceutical industry is also expected to boost market growth.
Segment Analysis
The global CAR T cell therapy market, by target antigen, has been segmented into CD19, CD22, and others. The CD19 target antigen segment accounted for a value of USD 342.56 million in 2018. On the basis of application, the global CAR T cell therapy market is segmented into acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and others.
Market Players
Market Research Future (MRFR) recognizes the following companies as key players in the global CAR T Cell therapy market that include Novartis AG (Switzerland), Pfizer, Inc. (US), Kite Pharma (US), Cellectis (France), Autolus Therapeutics PLC (UK), CARsgen Therapeutics (China), Juno Therapeutics (US), Sorrento Therapeutics (US), Legend Biotech (US), Mustang Bio (US), and others.
Regional Analysis
The global CAR T cell therapy market, based on region, is divided into the US, Europe, China, and the rest of the world.
The US is expected to hold the largest share of the global CAR T cell therapy market. This is owing to the increasing cases of cancer in the country. Europe showed a considerable amount of growth in the market due to an increase in the occurrences of hematologic cancer such as leukemia, lymphoma, and multiple myeloma. Europe held a market share of 9.15% in the global CAR T cell therapy market. China is estimated to significantly grow in the global market due to the developing healthcare infrastructure and increasing disposable income. Also, the market in the Middle East & Africa is expected to show the least growth owing to limited healthcare access and affordability among the population.
Key Findings of the Study
  • The Global CAR T cell Therapy Market is projected to reach USD 8716.06 Million by 2025 at a CAGR of 58.52% during the review period from 2019 to 2025.
  • The US accounted for the largest share of the global market due to the rising prevalence of cancer in the country.
  • The CD19 target antigen accounted for the largest target antigen segment, with a revenue of USD 56 million in 2018.
About Market Research Future: MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact:
+1 646 845 9312 | Email: sales@marketresearchfuture.com

Comments

Popular posts from this blog

Immunoassay Analyzers Market By Methods, Technologies, Clinical Review and Industry Outlook

  Immunoassay Analyzers Market  Research Report By Instruments (Immunofluorescence, Chemiluminescence, ELISA, Radioimmunoassay), Application (Infectious Diseases, Autoimmune Diseases, AIDS), End Users (Hospitals)- Global Forecast till 2023 Market Scenario Immunoassay analyzer is a device which measures the presence and concentration of proteins in analyte samples. These instruments are mostly used by pharmaceutical & biotechnological companies, laboratories, and research institutes. The global immunoassay analyzer market is driven by an increasing number of pharmaceutical and biotechnological companies, rising prevalence of different life-threatening diseases, and government’s initiatives for research & development activities. Furthermore, rapid development in diagnostic medical devices, increasing need for better drug treatment, and the increasing geriatric population had also fueled the market’s growth. On the other hand, high cost of instruments and poor reimburseme...

Laser Therapy Market Top Company Profiles, Latest Technology, Global Size, Industry Trends

  Laser Therapy Market  Research Report, By Type (Diode Lasers, Solid State Lasers, Gas Lasers, Dye Lasers, and others), By Application (Dermatology and Aesthetics, Surgery, Dental, Urology, Ophthalmology, and others) - Global Forecast from 2017 to 2023 Market Overview: Market Research Future (MRFR) anticipates strong CAGR of 9.2% in the global laser therapy market over the forecast period of 2017-2023. The expansion of the global laser therapy is the result of various market dynamics, out of which, the surging prevalence of diseases such as cataract and arthritis bears profound weightage. Laser therapy is the standard line of treatment in cases of cataract. Laser-based ophthalmology is highly preferred over other methods of treatment. YAG LASER, excimer LASER, femtosecond LASER, and others are the most commonly used lasers in ophthalmology. The widespread prevalence of cataract, as well as arthritis, promote the growth of the global laser therapy market. Expanding base of old...

Nonallergic Rhinitis Market Data, Technology Treatment and Diagnosis Management Overview

  Nonallergic Rhinitis Market  Share, Growth And Trends Analysis By Diagnosis (Physical Examination, Allergy Testing, And Imaging Test), By Treatment (Nasal Sprays, Nsaids), And By End User (Hospitals &, Clinics, Research Centers) - Global Forecast Till 2023 Market Highlights Nonallergic rhinitis, also known as vasomotor rhinitis is a medical condition that refers to a set of symptoms that resemble nasal allergies and hayfever (allergic rhinitis) occurring without a known cause. Some of the symptoms of non-allergic rhinitis include Postnasal drip, Runny nose, Sneezing, and Stuffy nose among others. Some patients with nonallergic rhinitis may even develop allergies and asthma eventually, hence treating the condition well in time becomes essential. Industry, Innovation & Related News November 08, 2018 – AstraZeneca Plc. (the UK), a multinational pharmaceutical and biopharmaceutical company announced the sale of its rights for asthma drug Alvesco (ciclesonide), nasal spra...